Fulgent Genetics (NASDAQ:FLGT) Stock Rating Upgraded by Zacks Investment Research

Fulgent Genetics (NASDAQ:FLGT) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Tuesday, Zacks.com reports. The firm currently has a $9.00 price target on the stock. Zacks Investment Research‘s price objective indicates a potential downside of 12.28% from the stock’s previous close.

According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to hospitals and medical institutions. Fulgent Genetics, Inc. is headquartered in Temple City, California. “

Several other equities analysts have also weighed in on FLGT. Credit Suisse Group lowered shares of Fulgent Genetics from an “outperform” rating to a “neutral” rating in a report on Friday, April 26th. Piper Jaffray Companies boosted their price target on shares of Fulgent Genetics from $5.30 to $9.50 and gave the company a “neutral” rating in a research note on Tuesday. Two analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $9.25.

NASDAQ:FLGT traded up $2.26 on Tuesday, hitting $10.26. The stock had a trading volume of 307,438 shares, compared to its average volume of 19,393. The company has a debt-to-equity ratio of 0.05, a quick ratio of 11.33 and a current ratio of 11.33. The firm has a market capitalization of $188.00 million, a PE ratio of -54.00 and a beta of 1.47. The stock has a fifty day moving average price of $6.46. Fulgent Genetics has a 1-year low of $3.02 and a 1-year high of $10.75.

Fulgent Genetics (NASDAQ:FLGT) last posted its earnings results on Monday, August 5th. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.06. The company had revenue of $8.42 million for the quarter, compared to analyst estimates of $6.42 million. Fulgent Genetics had a negative net margin of 20.33% and a negative return on equity of 7.12%. Analysts forecast that Fulgent Genetics will post -0.16 EPS for the current year.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes.

Recommended Story: Cash Asset Ratio

Get a free copy of the Zacks research report on Fulgent Genetics (FLGT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.